23andMe Holding Co.NASDAQ:ME
- LAST PRICE3.4600
- TODAY'S CHANGE (%)0.3200 (10.1911%)
- Bid / Lots3.4400/ 7
- Ask / Lots3.4800/ 12
- Open / Previous Close3.1200 / 3.1400
- Day Range
- 52 Week Range
- Volume153,180
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ME |
|---|---|---|
| 09:32 ET | 14524 | 3.2 |
| 09:33 ET | 336 | 3.205 |
| 09:42 ET | 2436 | 3.15 |
| 09:44 ET | 800 | 3.165 |
| 09:46 ET | 100 | 3.175 |
| 09:48 ET | 782 | 3.165 |
| 09:50 ET | 400 | 3.1771 |
| 09:51 ET | 101 | 3.173 |
| 09:55 ET | 1211 | 3.195 |
| 09:57 ET | 5462 | 3.2 |
| 10:00 ET | 1100 | 3.2 |
| 10:02 ET | 4634 | 3.3 |
| 10:04 ET | 4716 | 3.295 |
| 10:06 ET | 700 | 3.285 |
| 10:08 ET | 9476 | 3.26 |
| 10:09 ET | 100 | 3.31 |
| 10:11 ET | 3429 | 3.33 |
| 10:13 ET | 6888 | 3.3001 |
| 10:15 ET | 350 | 3.35 |
| 10:18 ET | 9907 | 3.3792 |
| 10:20 ET | 2921 | 3.355 |
| 10:22 ET | 300 | 3.355 |
| 10:26 ET | 970 | 3.3336 |
| 10:27 ET | 931 | 3.3236 |
| 10:31 ET | 702 | 3.3206 |
| 10:33 ET | 614 | 3.33 |
| 10:36 ET | 449 | 3.33 |
| 10:38 ET | 921 | 3.3215 |
| 10:40 ET | 193 | 3.325 |
| 10:42 ET | 500 | 3.33 |
| 10:44 ET | 550 | 3.3213 |
| 10:47 ET | 501 | 3.33 |
| 10:49 ET | 8573 | 3.415 |
| 10:51 ET | 1574 | 3.4239 |
| 10:54 ET | 1100 | 3.4 |
| 10:56 ET | 400 | 3.4057 |
| 10:58 ET | 577 | 3.4194 |
| 11:00 ET | 10483 | 3.4 |
| 11:02 ET | 6751 | 3.4723 |
| 11:03 ET | 3893 | 3.52 |
| 11:05 ET | 3457 | 3.505 |
| 11:07 ET | 1100 | 3.5295 |
| 11:09 ET | 200 | 3.506 |
| 11:14 ET | 1053 | 3.515 |
| 11:16 ET | 200 | 3.515 |
| 11:18 ET | 383 | 3.5182 |
| 11:20 ET | 874 | 3.49 |
| 11:21 ET | 700 | 3.4924 |
| 11:25 ET | 1678 | 3.48 |
| 11:27 ET | 1296 | 3.49 |
| 11:32 ET | 100 | 3.482 |
| 11:34 ET | 176 | 3.49 |
| 11:36 ET | 589 | 3.48 |
| 11:38 ET | 716 | 3.46 |
| 11:39 ET | 100 | 3.46 |
| 11:41 ET | 2475 | 3.4585 |
| 11:43 ET | 100 | 3.46 |
Nov 20, 2024
Nov 12, 2024
DJ 23andMe Makes Some Gains in Increasing Recurring Revenue -- Market Talk, from 11:57AM ET on Tuesday Nov 12, 2024 by Dow Jones
11:57AM ET on Tuesday Nov 12, 2024 by Dow JonesDJ 23andMe Considers Raising Capital as it Keeps Burning Cash -- Market Talk, from 11:47AM ET on Tuesday Nov 12, 2024 by Dow Jones
11:47AM ET on Tuesday Nov 12, 2024 by Dow JonesDJ 23andMe Lays Off 40% of Staff, Shuts Drug Development Business -- Update, from 9:52AM ET on Tuesday Nov 12, 2024 by Dow Jones
9:52AM ET on Tuesday Nov 12, 2024 by Dow JonesDJ 23andMe 2Q Loss Narrows After Disclosing Restructuring, from 8:03AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:03AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
23andMe Holding Co. | 75.7M | -0.1x | --- |
Exagen Inc | 67.7M | -4.2x | --- |
Cryo-Cell International Inc | 73.3M | -8.0x | --- |
American Well Corp | 139.6M | -0.7x | --- |
Auna SA | 532.9M | -15.2x | --- |
Oncology Institute Inc | 12.8M | -0.2x | --- |
Company Information
23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Contact Information
- Headquarters
- 349 Oyster Point BoulevardSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-938-6300
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Anne Wojcicki
- Chief Financial and Accounting Officer
- Joe Selsavage
- Lead Independent Director
- Mark Jensen
- Independent Director
- Andre Fernandez
- Independent Director
- Jim Frankola
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $75.7M |
|---|---|
Revenue (TTM) | $193.3M |
Shares Outstanding | 24.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.14 |
EPS | $-25.27 |
Book Value | $7.69 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -324.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
